New daily pill aims to save sight in diabetic eye disease
NCT ID NCT07459829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral medication, CU06-1004, for people with diabetic macular edema (DME), a condition that causes vision loss. About 156 participants will take either a low dose, high dose, or placebo pill daily for 24 weeks. The goal is to see if the drug improves vision and is safe, offering a potential easier treatment option than eye injections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a new eye injection preserve vision in south asians with diabetes?
- Could a biosimilar eye injection offer a new way to treat diabetic macular edema?
- Can a steroid implant boost the effect of standard eye injections for hard-to-treat diabetic macular edema?
- Can a new eye injection beat the current standard for diabetic vision loss?
- Eye injection aims to tame leading causes of blindness